Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Pfizer lifts annual sales forecast for COVID-19 vaccine

Published 2021-05-04, 06:55 a/m
© Reuters. FILE PHOTO: Serbia continues mass vaccination of its citizens against COVID-19

(Reuters) - Pfizer Inc (NYSE:PFE) on Tuesday raised its annual sales forecast for the COVID-19 vaccine it co-developed with Germany's BioNTech SE, as a vaccination drive across the globe intensifies.

The U.S. drugmaker now expects sales of $26 billion from the vaccine in 2021, up from its prior forecast of about $15 billion. The goal assumes that 1.6 billion vaccine doses will be delivered in the year.

Cost and gross profit from the vaccine are split 50-50 between Pfizer and BioNTech.

Pfizer has said it expects to profit from the vaccine, while some drugmakers including Johnson & Johnson (NYSE:JNJ) have said their vaccine will be available on a not-for-profit basis until the end of the pandemic.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.